Astral Systems closes £23M Series A to scale medical-isotope production
Bristol deeptech firm Astral Systems has closed a £23M Series A led by Mercia Ventures to scale production of medical isotopes used in cancer diagnosis and treatment.
Unlike most fusion companies still chasing long-term power generation, Astral already runs three commercial reactors and has earned more than £3M from research contracts.
Tees River, Daphni, Blast Club, and returning backers Speedinvest and Playfair also joined. The round brings total funding past £28M.
Every year, more than 50 million cancer scans and treatments rely on a handful of ageing nuclear reactors to produce radioactive materials. The UK makes almost none domestically.
When those reactors go offline, hospitals run short and patients wait. Shortages in 2009 and 2010, when Canada's Chalk River and the Dutch Petten reactor were both down, exposed how fragile the supply chain is.
Astral's answer is a compact "multi-state fusion" reactor that generates high-intensity neutron beams to irradiate target materials and produce isotopes.
With the new capital, it plans to run next-generation reactors at full capacity by the end of 2026 at the former Berkeley Power Station in Gloucestershire, a decommissioned nuclear site with grid connections and existing regulatory ties.
The company aims to reach profitability in 2027 and grow its team from 23 to more than 40 by the end of 2026.
Astral is not alone. SHINE Technologies in the US has raised more than $1 billion chasing the same radioisotope gap.
The startup also faces a tight runway: it must bring Actinium-225 or Lead-212, two isotopes used in targeted cancer therapies, to market by early 2027 to hit its profitability goal.
Astral, still an early-stage company, is taking an unusually grounded route for fusion, pairing institutional backers like Mercia Ventures and Speedinvest with three commercial reactors already running at real-world deployment. By selling medical isotopes today rather than promising electricity tomorrow, it is betting that revenue, not power generation, is fusion's faster path to market.
Read more: Tech Funding News
